Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Implication of Polymorphisms in DNA Repair Genes in Prognosis of Hepatocellular Carcinoma

  • Yue, Ai-Min (Department of Surgical Oncology, Xinxiang Central Hospital) ;
  • Xie, Zhen-Bin (Department of Surgical Oncology, Xinxiang Central Hospital) ;
  • Guo, Shu-Ping (Department of Surgical Oncology, Xinxiang Central Hospital) ;
  • Wei, Qi-Dong (Department of Surgical Oncology, Xinxiang Central Hospital) ;
  • Yang, Xiao-Wei (Department of Surgical Oncology, Xinxiang Central Hospital)
  • Published : 2013.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

XRCC1 genetic polymorphisms could be associated with increased risk of various cancer, including hepatocellular carcinoma (HCC), the fifth most common cancer. We here conducted a study to explore the role of selective SNPs of the XRCC1 and XPD genes in the prognosis of HCC. A total of 231 cases were collected, and genotyping of XRCC1 Arg194Trp, XRCC1 Arg399Gln, XPD Lys751Gln and XPD Asp312Asn was performed by duplex polymerase-chain-reaction with the confronting-two-pair primer method. Our findings indicated XRCC1 399Gln/Gln genotype was associated with a significant difference in the median survival time compared with patients carrying Arg/Trp and Arg/Arg genotypes, and individuals with XPD 751 Gln/ Gln genotype had a significantly greater survival time than patients carrying Lys/Lys and Lys/Gln genotypes. The Cox's regression analysis showed individuals carrying XRCC1 399Trp/Trp genotype had 0.55 fold risk of death from HCC than Arg/Arg genotype. Similarly, XPD 751Gln/Gln had a strong decreasein comparison to XPD Lys/Lys carriers with an HR of 0.34. These results suggest that polymorphisms in XRCC1 and XPD may have functional significance in the prognosis of HCC.

Keywords

References

  1. Azad AK, Bairati I, Samson E, et al (2012). Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival. Clin Cancer Res, 18, 196-206. https://doi.org/10.1158/1078-0432.CCR-11-1759
  2. Benhamou S, Sarasin A (2002). ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, 17, 463-9. https://doi.org/10.1093/mutage/17.6.463
  3. Biason P, Hattinger CM, Innocenti F, et al (2012). Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J, 12, 476-83. https://doi.org/10.1038/tpj.2011.33
  4. Bowen DG, Walker CM (2005). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature, 436, 946-52. https://doi.org/10.1038/nature04079
  5. Chen X, Sun H, Ren S, et al (2012). Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol, 14, 207-13. https://doi.org/10.1007/s12094-012-0785-3
  6. Giovannetti E, Pacetti P, Reni M, et al (2011). Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics, 12, 1641-52. https://doi.org/10.2217/pgs.11.109
  7. Han W, Kim KY, Yang SJ, et al (2012). SNP-SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population. Cancer, 118, 594-602. https://doi.org/10.1002/cncr.26220
  8. Hussain SP, Schwank J, Staib F, et al (2007). TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene, 26, 2166-76. https://doi.org/10.1038/sj.onc.1210279
  9. International Agency for Research on Cancer (2011). Liver cancer incidence and mortality worldwide in 2008; http://globocan.iarc.fr/factsheets/cancers/liver.asp. 2011.
  10. Jung SW, Park NH, Shin JW, et al (2012). Polymorphisms of DNA repair genes in Korean hepatocellular carcinoma patients with chronic hepatitis B: possible implications on survival. J Hepatol, 57, 621-7. https://doi.org/10.1016/j.jhep.2012.04.039
  11. Lavanchy D (2004). Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepat, 11, 97-107. https://doi.org/10.1046/j.1365-2893.2003.00487.x
  12. Mahimkar MB, Samant TA, Kannan S, et al (2012). Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mol Carcinog, 51, E94-103. https://doi.org/10.1002/mc.21868
  13. Mandal RK, Gangwar R, Kapoor R, et al (2012). Polymorphisms in base-excision & nucleotide-excision repair genes & prostate cancer risk in north Indian population. Indian J Med Res, 135, 64-71. https://doi.org/10.4103/0971-5916.93426
  14. Manuguerra M, Saletta F, Karagas MR, et al (2006). XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol, 164, 297-302. https://doi.org/10.1093/aje/kwj189
  15. Pang R, Tse E, Poon RT (2006). Molecular pathways in hepatocellular carcinoma. Cancer Lett, 240, 157-69. https://doi.org/10.1016/j.canlet.2005.08.031
  16. Ramachandran S, Ramadas K, Hariharan R (2006). Single nucleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol, 42, 350-62. https://doi.org/10.1016/j.oraloncology.2005.08.010
  17. Rybarova S, Vecanova J, Hodorova I, et al (2011). Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer. Med Sci Monit, 17, BR354-63.
  18. Shen MR, Jones IM, Mohrenweiser H (1998). Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer research, 58, 604-8.
  19. Slyskova J, Naccarati A, Pardini B, et al (2012). Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls. Mutagenesis, 27, 225-32. https://doi.org/10.1093/mutage/ger088
  20. Smith TR, Miller MS, Lohman K, et al (2003). Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett, 190, 183-90. https://doi.org/10.1016/S0304-3835(02)00595-5
  21. Xu C, Wang X, Zhang Y, et al (2011). Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 14, 912-7.
  22. Yu MW, Yang SY, Pan IJ, et al (2003). Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst, 95, 1485-8. https://doi.org/10.1093/jnci/djg051
  23. Zhang H, Li W, Franklin MJ, et al (2011). Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis. Anticancer Res, 31, 3945-52.

Cited by

  1. Genetic polymorphisms of XRCC1 gene and susceptibility to hepatocellular carcinoma in Chinese population vol.31, pp.4, 2014, https://doi.org/10.1007/s12032-014-0887-6
  2. Association Between XPD Lys751Gln and Asp312Asn Polymorphisms and Hepatocellular Carcinoma Risk vol.93, pp.29, 2014, https://doi.org/10.1097/MD.0000000000000330
  3. A/G Polymorphism and Hepatocellular Carcinoma Risk: a Meta-Analysis vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.3009
  4. 53 mutation at codon 249 predict clinical outcomes of hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A cohort study for 10 years’ follow up vol.46, pp.8, 2015, https://doi.org/10.1111/hepr.12611
  5. Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization vol.20, pp.4, 2016, https://doi.org/10.1089/gtmb.2015.0267